Abstract Introduction Clinical trials that led to the Food and Drug Administration (FDA) approval of systemic cancer therapies have generally excluded patients with autoimmune disease (AID) due to concerns about increased immune-related adverse events (irAEs), disease flares, and potential reductions in the efficacy of immunotherapies. Objective To evaluate the optimal...
ABSTRACT Introduction: Well-differentiated neuroendocrine pulmonary tumours (NETp) are morphologically classified as typical carcinoid (TC) and atypical carcinoid (AC). There are limited data on systemic treatment for metastatic disease. Objective: Our study evaluated the median progression-free survival of patients with metastatic tumours, comparing TC and AC status for different treatments. Methods: Retrospective series...
